Tempus AI Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Tempus AI (TEM) is scheduled to release second-quarter earnings on August 8, with analysts anticipating a reduced loss of 25 cents per share and substantial revenue growth to $297.76 million, up from $165.97 million year-over-year. The company recently secured a significant regulatory win with FDA 510(k) clearance for its ejection fraction software on July 16, which contributed to a 5.8% share gain on Thursday. Analyst sentiment remains largely positive, with multiple firms maintaining or initiating Buy ratings and increasing price targets, despite a recent downgrade from JP Morgan which still raised its price target.

Analysis

Tempus AI is approaching its second-quarter earnings report with significant positive momentum, underpinned by strong operational and market signals. Analysts project a substantial year-over-year revenue increase to $297.76 million from $165.97 million, representing nearly 80% growth, alongside a marked improvement in profitability with an expected loss of 25 cents per share compared to 63 cents a year prior. This bullish financial outlook is further bolstered by a key regulatory milestone: the recent FDA 510(k) clearance for its ejection fraction software, which has likely contributed to the stock's 5.8% gain to $58.74. While analyst sentiment is largely positive, with three 'Buy' ratings and price targets as high as $74, there are notes of caution. Both JP Morgan and Piper Sandler hold 'Neutral' ratings, although both firms recently increased their price targets, suggesting their concerns may relate more to valuation than to fundamental business prospects following the stock's appreciation.

Key Decisions for Investors

• Investors should monitor the upcoming earnings release on August 8 for confirmation that the company can meet or exceed the high bar of nearly 80% YoY revenue growth, as this is a key driver of the current valuation.
• Pay close attention to management's forward-looking guidance, particularly regarding the commercialization strategy and expected revenue contribution from the newly FDA-cleared ejection fraction software.
• Given the recent share price run-up and the mixed analyst ratings, consider the risk of a 'sell-the-news' event, and weigh the potential for a valuation-driven pullback even if quarterly results are strong.